

Belgravia Appoints Dr. Sam Hanna Chief Medical Officer of Cannabis Dermatology Division

TORONTO, April 18, 2018 -- BELGRAVIA CAPITAL INTERNATIONAL INC. (CSE:BLGV) (OTCQB:BLGVF) ("Belgravia" or the "Company") has appointed Dr. Sam Hanna as Chief Medical Officer of its cannabis dermatology division. Dr. Hanna is a well-recognized Canadian dermatologist with experience in numerous clinical studies for dermatology drugs across North America.

Belgravia Dermatology Division – ICP Organics:

The Company announced the appointment of Dr. Hanna on January 10, 2018, as Special Advisor to Belgravia's wholly owned subsidiary, ICP Organics. Dr. Hanna now assumes leadership for all medical aspects of development of cannabinoid based active pharmaceutical ingredients for dermatological conditions. Dr. Hanna, with the assistance of a biotechnology consultant, has completed initial market studies. The Company has selected specific dermatological indications for topical application of medically claimed drugs. Dr. Hanna is currently engaged in careful analysis of relevant scientific studies in order to establish developmental approaches. This includes selecting biological markers and drug delivery methodologies. He will also add to the technical team and build out regulatory, and marketing staff and consultants. Dr. Hanna has previously participated in numerous dermatology clinical studies.

Dr. Sam Hanna, Chief Medical Officer of ICP Organics stated: "There are currently dermatological conditions, such as certain types of dermatitis and psoriasis where the medical needs are not yet fully satisfied by current treatments. There is good evidence that cannabinoids may provide therapeutic value. I am excited to be working with ICP Organics in the development of cannabinoid-related ethical drug products. For example, Cannabidiol has been associated with reduced keratinocyte proliferation and lipostatic effects. Related molecules have relevant effects in dermatology impacting androgenicity and inflammation. We are currently adding to the technical team and working on establishing intellectual property strategies. In addition, we are defining the scope of the necessary pre-clinical work that will lead to Phase 1 clinical trials."

Mr. Mehdi Azodi, President and Chief Executive Officer of the Company stated: "We are pleased to welcome Dr. Hanna as Chief Medical Officer. When Dr. Hanna joined the Company, initially as special advisor, we made reference to the fact that the Cannabinoid market is growing rapidly and that according to the Journal of Clinical Investigation there is sufficient scientific data to strongly encourage future study in clinical trials in skin disease areas. In addition to carrying out ethical drug work we are also defining faster-to-market products, which will be marketable in Canada on an accelerated basis as the House of Commons and the Senate approve the new cannabis legislation. Such products may include claimed products that would likely be regulated, in part, as Natural Health Products. Longer-term ethical products are those that would be regulated under the Food and Drugs Act in Canada and the Food and Drug Administration in the United States. Both areas are of interest to us."

Mr. Azodi continued: "We expect to make a series of announcements over the next few weeks regarding Belgravia and ICP Organics developments in this area. Dr. Hanna, with the assistance of another medical advisor, Dr. Shoaib Sheikh, and other biotechnology consultants are advancing our plans aggressively. We are also engaging at present patent attorneys and laboratories experienced in pre-clinical and clinical testing and the handling of cannabis-derived ingredients."

Dr. Hanna will be joining the Board of Directors of ICP Organics. Ms. Genevieve Roch-Decter and Ms. Nicole Marchand are stepping down from the Board but will continue as consultants. Additional Board appointees can be expected in the near term.

The Company is grateful to Ms. Roch-Decter and Ms. Marchand for their contributions to the Company in its various stages of development. They will continue to provide financial advisory services to Belgravia Capital.

Belgravia Capital Business Model:

Belgravia continues to take a multi-tiered approach in the development of its licit cannabis value added portfolio of investments and operating businesses. Belgravia Incubator identifies and finances early stage companies where Belgravia believes it can add value. Belgravia Holdings makes measured investments in public and private companies, primarily Cannabis related, but also in technology verticals. Belgravia Royalty and Management Services has developed a targeted royalty and fee income model, with revenues currently in place. Additional specific information about the diversified model will be provided over the coming weeks.

About Belgravia

Belgravia Capital International Inc. is focused on its three core business divisions: Incubation, Investments and also Royalty and Management Services. Belgravia will also develop new companies with a focus on the cannabis industry. The Incubation division will provide services to support the development of early-stage companies in the Cannabis space and other technology areas. Belgravia Holdings, the Investments division, invests in various private and public companies with a focus on licit

cannabis, technology, and, on an opportunistic basis, resources. Belgravia and Royalty and Management Services has developed a targeted royalty and fee income model.

In the Cannabis space, the Company's geographic focus is primarily in Canada. Further, the developing cash and investment asset base can also support international expansion on a selective basis. Canada has powerful national government legislation leadership in Cannabis, Cannabis friendly and supportive physicians, and the world's strongest Cannabis capital markets.

For more information, please visit www.belgraviacapital.ca

Forward-Looking Statements

Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements include statements that use forward-looking terminology such as "may", "will", "expect", "anticipate", "believe", "continue", "potential" or the negative thereof or other variations thereof or comparable terminology. Such forward-looking statements include, without limitation, statements regarding planned investment activities & related returns, trends in the markets for fertilizers and medicinal or recreational use of cannabis, the timing or assurance of the legalization of recreational cannabis, the timing for completion of research and development activities, the potential value of royalties from water and other resources, and other statements that are not historical facts. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company, including, but not limited to, changes in market trends, the completion, results and timing of research undertaken by the Company, risks associated with resource assets, the impact of general economic conditions, commodity prices, industry conditions, dependence upon regulatory, environmental, and governmental approvals, the uncertainty of obtaining additional financing, and risks associated with cannabis use for medicinal or recreational purposes. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements.

For More Information, Please Contact:

Mehdi Azodi, President & CEO
Belgravia Capital International Inc.
(416) 779-3268
mazodi@blgv.ca